What’s New in the CTN?
Updates from the NIDA National Drug Abuse Treatment Clinical Trials Network. Want to share some news about your protocol, node, publications or presentations, or other CTN-related work here and/or in the CTN Bulletin? Email us at ctnlib@uw.edu!
News from the New England Consortium Node
NIDA News Release Buprenorphine initiation in the ER found safe and effective for individuals with OUD who use fentanyl. NIDA News, March 30, 2023. Referencing findings: D’Onofrio G, Hawk KF, Perrone J, et al. Incidence of Precipitated Withdrawal During a Multisite Emergency Department–Initiated Buprenorphine Clinical Trial in the Era of Fentanyl. JAMA Netw Open. 2023;6(3):e236108. doi:10.1001/jamanetworkopen.2023.6108 New Publication Kropp FB, Smid MC, Lofwall MR, Wachman EM, Martin PR, Murphy SM, Wilder CM, Winhusen TJ. Collaborative care programs for pregnant and postpartum individuals with opioid use disorder: Organizational characteristics of sites participating in the NIDA CTN0080…
New in the Library: March & April 2023
March-April 2023 Here are the newest items added to the Library in March and April 2023: Collaborative Care Programs for Pregnant and Postpartum Individuals with Opioid Use Disorder: Organizational Characteristics of Sites Participating in the NIDA CTN0080 MOMs Study. Kropp FB, et al. Journal of Substance Use and Addiction Treatment 2023;149:209030. CTN-0080 Surmounting Withdrawal to Initiate Fast Treatment with Naltrexone (SWIFT): A Stepped Wedge Hybrid Type 1 Effectiveness-Implementation Study. Greiner MG, et al. Contemporary Clinical Trials 2023 (in press). CTN-0097 Optimizing Recruitment and Retention in Substance Use Disorder Research in…
News from the Western States Node
CTN Western States Node investigators Dan Hartung and Elizabeth Waddell recently published findings from their CDC-funded project, Reducing Overdose After Release from Incarceration (PI: Waddell) that demonstrate risk of fatal and non-fatal opioid overdose risk is 10x greater among Oregon adults releasing from prison than in the state’s general population. Risk is even higher among women, those with documented substance use disorder and mental health treatment needs, and in the two weeks post release. Read the article in JSAT here. These findings are already driving policy discussions in Oregon and were…
Webinar: The Greater Intermountain Node (GIN): Where We Were, Where We Are, and Where We Will Be (April 18, 12pm MT)
Presenter: Adam J. Gordon, MD, MPH, FACP, DFASAMApril 18, 2023 | 12:00-1:00 PM MST In this presentation, Dr. Gordon will describe the origination, present status, and future opportunities of the CTN Greater Intermountain Node (GIN). He will describe the mission and aims of GIN, as well as the three studies originating from the Node and six studies hosted by it. Dr. Gordon will emphasize the remarkable research and clinical collaboration across the University of Utah campus and greater Intermountain area. He will also discuss the robust mentored training of the…
CTN Youth SIG Webinar: Getting Evidence-Based Treatments to Youth and Families Who are Involved in the Juvenile Legal System (May 19, 11am ET)
The CTN Youth SIG is pleased to invite you to an upcoming presentation/webinar: Getting Evidence-Based Treatments to Youth and Families Who are Involved in the Juvenile Legal System Ashli J. Sheidow, PhD, Senior Research Scientist, Oregon Social Learning CenterFriday, May 19th, 2023 (11:00 a.m.–12:00 p.m. ET) Dr. Sheidow’s services research examines methods and tools for getting substance use interventions to youth with juvenile legal system involvement. She will present lessons learned, with a focus on a task-shifting study with juvenile probation officers delivering contingency management treatment to youth and their parents/caregivers. The…
NEWS: US FDA approves Narcan (4mg naloxone nasal spray) for over-the-counter purchase/use
(From the US FDA press release) Today, the U.S. Food and Drug Administration approved Narcan, 4 milligram (mg) naloxone hydrochloride nasal spray for over-the-counter (OTC), nonprescription, use – the first naloxone product approved for use without a prescription. Naloxone is a medication that rapidly reverses the effects of opioid overdose and is the standard treatment for opioid overdose. Today’s action paves the way for the life-saving medication to reverse an opioid overdose to be sold directly to consumers in places like drug stores, convenience stores, grocery stores and gas stations,…
Protocol Update: CTN-0139
March 15, 2023 CTN-0139, the Collaborative Care for Polysubstance use in Primary Care Settings (Co-Care) Trial, is studying a collaborative care intervention for polysubstance use involving opioids and/or stimulants, in adult primary care patients. Collaborative care is a team-based approach to managing chronic conditions that has been effective for depression and other behavioral health conditions, and has the potential to transform the delivery of substance use treatment in primary care settings. This HEAL-funded CTN trial will test the Co-Care model versus enhanced usual care to reduce substance use and improve…
Recording Available: Cultural Considerations for Addiction Research: Looking to the Past to Inform the Future
The Office of Research Training, Diversity, and Disparities is offering a series titled Profiles of Excellence: Focus on Diversity. This webinar, held on March 6, 2023 from 4-5pm EST, featured Ayana Jordan, MD, PhD, of NYU Grossman School of Medicine, talking about “Cultural Considerations for Addiction Research: Looking to the Past to Inform the Future.” View the recording here. (Passcode: Yyr!6b?j)
Webinar: Injectable XR Buprenorphine: A Better Mousetrap or a Paradigm Shift in MOUD (April 6, Northeast Node)
Join the CTN Northeast Node on April 6, 2023 (12pm-1pm ET) for the latest in their Science Series: Injectable XR Buprenorphine: A Better Mousetrap or a Paradigm Shift in MOUD? with Eva Quirion, NP, PhD This presentation will explore the science behind extended release (XR) buprenorphine and field experiences in the use of XR buprenorphine in a primary care setting. This talk will also address ways to bring this medication to patients and if this treatment makes financial sense. 1.0 AMA PRA Category 1 CME available! Join the Zoom meeting here (no…
REGISTER NOW! CTN Annual Steering Committee Meeting: April 24-26, 2023
March 2, 2023 Registration is now open for this year’s CTN Annual Steering Committee Meeting, April 24-26, 2023! The 2023 CTN Annual Steering Committee Meeting is being held in-person at the Bethesda North Marriott Hotel and Conference Center (book your reservation here!) in Rockville, Maryland, from April 24–26, 2023. For those unable to attend in person, all plenary sessions and some ancillary sessions will be broadcast via Zoom. The level of interaction available virtually will vary by session. Both in-person and virtual attendees will register on the Zoom Events platform: Both methods…
NIDA HIV Research Program Seminar: Substance Use and HIV Latency (April 26, 1-2pm ET)
Mark your calendars for Wednesday April 26th, 1-2 pm ET for this unique opportunity to interact with a leading researcher at the intersection of HIV and substance use. The NIDA HIV Research Program (HRP) is pleased to announce the next presentation in its Seminar Series: A vicious cycle: The impact of inflammation and substance use on the control of HIV latency in microglia by Dr. Jonathan Karn, Reinberger, Professor & Chair of the Department of Molecular Biology & Microbiology at Case Western Reserve University School of Medicine. Dr. Karn has been studying transcriptional…
Job posting: NIDA Program Official/Program Specialist and Two Contractor Positions
February 13, 2023 NIDA is hiring for this new program, named American Indian and Alaska Native Collective Research Effort to Enhance Wellness Program (AIAN CREW). In brief, the NIH HEAL Initiative is funding a program to support Tribes and American Indian/Alaska Native (AI/AN) serving organizations and communities to respond to the opioid/drug overdose crisis by establishing or expanding research infrastructure and capacity for Tribal research entities to conduct research related to all facets of the opioid/overdose crisis, including substance misuse, mental health related factors, and the management of pain. It…
Save the Date & Call for Posters: 2023 CTN Steering Committee Meeting, April 24-26
February 3, 2023 Save the Date The 2023 CTN Steering Committee meeting will be held at the Bethesda North Marriott Hotel & Conference Center (North Bethesda, MD) on April 24-26, 2023. More information on registration and logistics coming soon! Call for Posters Sharing of the results, experiences, techniques, and observations from performing our trials is a critical and exciting part of the CTN experience. To that end, CTN members are encouraged to submit posters for display at the 2023 CTN Annual Steering Committee Meeting Poster Session to be held on…
Missing the Mark: Medication Access in Specialty Addiction Treatment Settings for Youth with OUD (March 17, 11amPT)
February 2, 2023 The CTN Youth SIG is pleased to invite you to an upcoming presentation/webinar: Missing the Mark: Medication Access in Specialty Addiction Treatment Settings for Youth with Opioid Use DisorderMarch 17, 2023 | 11am-12pm PT Justine W. Welsh, MD, Associate Professor, Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine The objectives of the presentation are to 1) Describe a decreasing trend in buprenorphine prescribing for youth with opioid use disorder (OUD) 2) Recognize attitudes/beliefs among addiction treatment providers towards medication for OUD in youth 3) Propose new areas…
NIDA INVEST Postdoctoral Fellowship International Scholars – Special Application Deadline: April 1, 2023
January 25, 2023 NIDA International Program is accepting applications for international postdoctoral researchers for the INVEST Drug Use and Addiction Research Fellowship. This combines postdoctoral research training in the United States with professional development activities and grant-writing guidance to form a unique program for drug use and addiction scientists. Fellowship: The 12-month INVEST fellowship provides rigorous postdoctoral research training with a NIDA grantee at a U.S. institution, professional development activities that help establish personal relationships with NIDA grantees and NIDA officials, a stipend for living and personal expenses, and an allowance to cover…
CTN & ATTC Webinar: Digital Therapeutics in the Treatment of SUD (Feb 15, 11am PT
February 15, 2023 | 11am-12:30pm PT | Register here! Digital therapeutics–software used to prevent, treat, or manage a medical disorder or disease–are redefining the future of healthcare. Digital therapeutics package an entire model of care that can be delivered with fidelity and in accordance with state-of-the-science best practices into a unified, seamless digital delivery system. Digital therapeutics have been particularly transformative in the field of substance use, mental health, and other behavioral health conditions and can markedly improve access to care, quality of care, and treatment outcomes, while reducing costs,…
News from the Northeast Node: Science Series Update
January 8, 2023 Northeast Node Science Series kicks off its ’22-23 Academic Year with an in-depth review of cannabis as a potential pharmacological adjunct to MOUD In November 2022, the Northeast Node welcomed Dr. Ziva Cooper of the UCLA Center for Cannabis & Cannabinoids to kick off the Node’s ’22-23 Academic Year Science Series. Dr. Cooper’s presentation, “Cannabis and Opioids: Promising pharmacology to address the opioid epidemic?” gave a brief overview of cannabis and the pharmacology of phytocannabinoids. Preclinical studies and randomized controlled trials have examined the potential for cannabinoids…
New Articles from CTN-0049 (Project HOPE) and CTN-0073 (PROUD)
January 8, 2023 Added to the CTN Dissemination Library recently: Differential effects of patient navigation across latent profiles of barriers to care among people living with HIV and comorbid conditions.Traynor SM, et al. Journal of Clinical Medicine 2023;12:114. This paper reports on a study analyzing data from CTN-0049 (Project HOPE) to see if patient navigation interventions (with and without contingency management) are effective at increasing engagement in HIV care and viral suppression for people living with HIV. Find it in the CTN Dissemination Library. Baseline representativeness of patients in clinics…
Protocol News: CTN-0100
December 8, 2022 In November, the CTN-0100 Project Team launched a month-long BINGO challenge aimed at boosting recruitment across the 18 study sites. BINGO squares included hitting (or exceeding!) randomization targets for the month, reuniting with a missing participant, and completing internal QA. The Adapt site from the Western States Node and the SSTAR site from the New England Consortium Node were the first sites to “BINGO”, just 16 days into the challenge (see photos of the winning team below)! 7 additional sites achieved “BINGO” by the end of the…
Webinar: The Effectiveness & Utility of Telebehavioral (Telehealth) Services, Nov. 2, 11am PT
The goal of the National Institute of Drug Abuse (NIDA) Clinical Trials Network/Addiction Technology Transfer Center (ATTC) webinar series is to help scholars and clinicians in the addiction field stay abreast of cutting-edge science. This series is sponsored by the Western States Node of the CTN and the Pacific Northwest and Pacific Southwest ATTCs. The uptake in the use of telebehavioral services since the start of the Public Health Emergency (PHE) has been swift and is significantly transforming how behavioral health services are delivered. This is encouraging, as the research base…